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INTRODUCTION
Starting in 1942, the United States Patent & Trademark Office
(USPTO) has allowed patents to be issued for cannabis-related innovations.1
*

Dawson Hahn, J.D. Candidate 2020, is a part-time Juris Doctorate Candidate at Concordia
University School of Law, Editor-in-Chief of Concordia Law Review, and a full-time
Software Engineer at Micron Technology, Inc. He would like to thank his friends and family
for their support and motivation during the writing process. He would also like to thank
Associate Dean Latonia Haney Keith and Associate Professor McKay Cunningham for their
insight and guidance throughout his law school career.
1
Eric Furman & Ari Feinstein, Patent Protection for Cannabis?, PHARMACEUTICAL
EXECUTIVE (Nov. 13, 2018), http://www.pharmexec.com/patent-protection-cannabis.
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Yet, the possession, cultivation, and distribution of marijuana has been
outlawed since 1970 under the Controlled Substances Act (CSA).2 How can
this be? This juxtaposition of cannabis and patents has led to many questions
in the cannabis and intellectual property fields. Since there remains no
legality requirement to secure a patent, the USPTO has been able to issue
seemingly valid patents for cannabis and cannabis-related innovations.
However, in bringing an infringement case for a cannabis-related patent, the
patent owner is likely to detail activities that are currently illegal under
federal law. How will that play out? Are these patents really valid? Will the
federal courts enforce a cannabis-related patent? What kind of patent
protections are available for a cannabis-related invention? These questions
have gone unanswered so far because the courts have not heard a patent
infringement case involving a cannabis-related patent. Until now.
On July 30th, 2018, United Cannabis Corporation filed a complaint
for patent infringement against Pure Hemp Collective, Inc. in the US District
Court for the District of Colorado.3 Recreational cannabis use has been
legalized in the state of Colorado,4 but patent infringement cases are a matter
of federal law, where cannabis is still illegal. 5 United Cannabis Corporation
only asserted one patent in its complaint: U.S. Patent No. 9,730,911 (the ‘911
Patent).6 The ‘911 Patent claims various liquid formulations of highly
enriched extracts of plant cannabinoids and has seven independent claims.7
As the CSA currently bans any “material, compound, mixture, or
preparation” which contains any quantity of tetrahydrocannabinols or
cannabimimetic agents, each of these claims describe a liquid formulation
that would be illegal under federal law.8 In addition to United Cannabis
Corporation’s suit, the Department of Justice and the Drug Enforcement
Administration recently announced that Epidiolex, “the first FDA-approved
drug made from the cannabis plant,” was reclassified as a Schedule V drug

2

See Controlled Substances Act, 21 U.S.C. § 812 (1970).
Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis Corp. v.
Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017).
4
COLO. REV. STAT. ANN. CONST. art. XVIII, § 16.
5
21 U.S.C. § 812 Schedule I(c) (2012).
6
Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis (No. 1:18cv-01922-NYW).
7
See U.S. Patent No. 9,730,911 (filed Oct. 21, 2015) (patenting the extraction of
pharmaceutically active components from plant materials).
8
Controlled Substances Act, § 812 Schedule I(c).
3
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under the CSA.9 Does that mean that cannabis itself will soon be reclassified?
That remains unclear. Since federal law still prohibits marijuana, any state
laws that legalize marijuana seem to be at odds with federal law. While the
10th Amendment protects a state’s ability to govern itself, the Supremacy
Clause prevents state law from contradicting federal law.10 Thus, it seems
like marijuana laws at the state level conflict with federal law unless
marijuana is reclassified under federal law, which seems unlikely under the
current administration.11 But maybe there’s another option.
This Comment will examine the interactions of patent laws and
cannabis laws in the United States. Section I sets forth a brief history of patent
laws, while also detailing the requirements in obtaining a patent, and how one
may infringe on a patent. Section II discusses the present status of cannabisrelated patents, introduces United Cannabis Corp. v. Pure Hemp Collective,
Inc., and debates possible outcomes of the case. Section III debates the
legality of cannabis in America and the impact of Federalism and the
Supremacy Clause to state cannabis laws and proposes a solution to the
dichotomy between state and federal cannabis laws.
I. PATENT LAW OVERVIEW
A.

The U.S. Patent System

Intellectual property can be thought of as “any product of the human
intellect that the law protects from unauthorized use by others.”12 Intellectual
property covers a large area of law, including patents, trademarks, copyrights,
and trade secrets. Under Article I of the U.S. Constitution, Congress is given
the power “[t]o promote the Progress of Science and useful Arts, by securing
for limited Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries.”13 State and federal lawmakers have
parlayed this enumeration into the federal Patent Act and federal Copyright
Act, as well as other state and federal laws, which make up our basic
9

Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved
Drugs Containing Cannabidiol, 83 Fed. Reg. 48,950 (Sept. 28, 2018).
10
U.S. CONST. art. VI, cl. 2.
11
See generally Memorandum from Attorney Gen. Jefferson B. Sessions, III to all United
States Attorneys (Jan. 4, 2018) [hereinafter Sessions Memo] (available at
https://www.justice.gov/opa/press-release/file/1022196/download).
12
Intellectual Property, CORNELL LAW SCHOOL,
https://www.law.cornell.edu/wex/intellectual_property (last visited Mar. 29, 2019).
13
U.S. CONST. art. I.
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intellectual property laws.14 Businesses, entities, and individuals all rely on
intellectual property to further their economic goals. While each intellectual
property right is significant in its own way, especially in the growing
cannabis industry, this Comment focuses specifically on patents.
Up until Congress passed the first federal Patent Act, patent
protections were offered by state legislatures.15 Enacted in 1790, the first
federal Patent Act was America’s first attempt at codifying the federal patent
laws we have today.16 Since then, Congress has made significant changes to
our federal patent laws, including a major overhaul of the Patent Act in 195217
and the America Invents Act of 2011.18 While the original Patent Act has
been modified and updated, many key terms and concepts from the 1790 Act
have survived to the present day.19 Today’s federal Patent Act grants a
patentee the right to exclude all others from making, using, offering for sale,
and selling the patented invention within the United States, just as the 1790
Act did.20
Patent law helps promote progress in the sciences and the useful arts
by giving inventors a limited right to exclude others from using their new
inventions or methods without permission.21 Additionally, patent law helps
accomplish two other important goals. First, the patent system helps to
publicize inventions. Inventors must provide a written disclosure of their
innovation which allows those skilled in the field to make and use the
invention.22 This makes a public record of progress in the field of innovation
and allows the general public to receive meaningful disclosure of new
innovations.23 Second, patent laws help to reduce the risks of inadvertent
disclosure and unprovable theft.24 As patent law does not require proof that
an infringer directly copied or even knew of the patent in question, one who
14

LYDIA PALLAS LOREN & JOSEPH SCOTT MILLER, INTELLECTUAL PROPERTY LAW: CASES
& MATERIALS 4–6 (6th ed. 2018).
15
Herbert Hovenkamp, The Emergence of Classical American Patent Law, 58 ARIZ. L. REV.
263, 267 (2016).
16
Patent Act of 1790, Ch. 7, 1 Stat. 109–12 (amended 1793).
17
Patent Act of 1952, Pub. L. No. 82-593, 66 Stat. 792 (1952).
18
Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).
19
35 U.S.C. § 271 (2015).
20
Id.; see also Patent Act of 1790 § 4.
21
See LOREN & MILLER, supra note 14, at 125.
22
35 U.S.C. § 111 (2015).
23
See LOREN & MILLER, supra note 14, at 125.
24
Colleen V. Chien, Opening the Patent System: Diffusionary Levers in Patent Law, 89 S.
CAL. L. REV. 793, 818 (2016).
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is using the invention disclosed in the patent without permission is liable for
infringement.25 As a result, innovators that leverage the protections of patent
law need not maintain secrecy from competitors or the public. This helps to
strike a bargain between the public and the field of inventors to keep the
nation abreast of new technologies, as well as granting protections to the
inventors themselves; i.e., “fair notice for fair protection.”26
B.

Obtaining a U.S. Patent

As patent prosecution is solely a matter of federal law, U.S. patents
can only be granted by the U.S. Patent & Trademark Office (USPTO). There
are a series of formal administrative processes that must be completed at the
USPTO in order to obtain patent protection.27 Generally, the patent
prosecution process begins when an inventor files an application for a
patent.28 This application will describe the invention and enable a
hypothetical “person skilled in the art” to make and use the invention.29 While
the description is certainly an important aspect of the application, the most
important part of the application are the claims specified. These claims state
the subject matter that the inventor regards as her invention.30 More notably,
these claims “state the legal boundaries of the products (or processes) that the
patent owner can exclude others from making, using, selling, offering to sell,
or importing into the U.S.”31
Filing an application is not the only obstacle a party needs to
overcome in order to be granted a patent. A patent claim must be supported
by the written disclosures in the application,32 in addition to meeting the
substantive requirements of patent law. As codified in the United States
Code, Section 101 of Title 35 details the functional requirements of a patent:
“Whoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
25

35 U.S.C. § 271(a) (2015).
See LOREN & MILLER, supra note 14, at 126.
27
35 U.S.C §§ 111–123 (2015).
28
Id. § 111.
29
Id. § 112(a); see also LOREN & MILLER, supra note 14, at 126–27 (“The application, if
properly prepared, describes the invention and, through that description, enables the
hypothetical person having ordinary skill in the art—often called the phosita—to make and
use the invention.”).
30
Id. § 112(b).
31
See LOREN & MILLER, supra note 14, at 127.
32
Id.
26
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thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title.”33 These substantive requirements are broken down
into four areas: patentable subject matter, utility, novelty, and
nonobviousness.
In regards to patentable subject matter, the federal law seems clear
that human intervention is key to three of the groups: machines,
manufactures, and the composition of matters that do not occur naturally.34
On the other hand, the Supreme Court has held that “[l]aws of nature, natural
phenomena, and abstract ideas are not patentable.”35 However, at some level,
all inventions use or apply laws of nature and abstract ideas, so the Court has
pointed out that “a process is not unpatentable simply because it contains a
law of nature or a mathematical algorithm.”36 Thus, the patentability of an
invention or process falls upon whether the invention transforms the abstract
idea into a “new and useful end.”37 The utility bar of Section 101 is not hard
to meet—to be considered useful, an invention or process must be capable of
providing some identifiable benefit.38
The novelty bar, which is codified in Section 102, can be more
difficult to get past.39 Generally speaking, the novelty requirement allows for
only new inventions to be patentable: “Congress may not authorize the
issuance of patents whose effects are to remove existent knowledge from the
public domain, or to restrict free access to materials already available.”40
While out of the scope of this Comment, the framework for novelty currently
exists in two different forms because of the changes made by the America
Invents Act of 2011.41 The new Section 102 governs all patents whose
applications were filed on or after March 16, 2013, and focuses on the filing
data of the application, whereas the previous version of Section 102 focused

33

35 U.S.C § 101 (2015).
See LOREN & MILLER, supra note 14, at 165 (“‘[M]achines’ and ‘manufactures’ are not
found in nature, and naturally occurring materials are not ‘compos[ed]’”).
35
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 589 (2013)
(quoting Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66, 66
(2012)).
36
Parker v. Flook, 437 U.S. 584, 590 (1978).
37
Id. at 591.
38
Brenner v Manson, 383 U.S. 519, 534 (1966).
39
35 U.S.C. § 102 (2015).
40
Graham v. John Deere Co. of Kan. City, 383 U.S. 1,6 (1966).
41
Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 285–86 (2011).
34
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on the actual invention date.42 Finally, an invention must be nonobvious in
order to obtain patent protections. Under Section 103, a claimed invention
may be considered obvious “if the differences between the claimed invention
and the prior art are such that the claimed invention as a whole would have
been obvious before the effective filing date of the claimed invention to a
person having ordinary skill in the art to which the claimed invention
pertains.”43 If a claimed invention meets all of these substantive
requirements—patentable subject matter, utility, novelty, and
nonobviousness—it is then available for federal patent protections.
C.

Patent Infringement

In most cases, a patent, and the subsequent rights awarded by it, are
in force from the date the patent was issued until 20 years from its original
filing date.44 These rights given to the patentee protect the patent from being
either directly or indirectly infringed upon. The Patent Act helps to define
these rights by listing some activities that constitute infringement: “whoever
without authority makes, uses, offers to sell, or sells any patented invention,
within the United States or imports into the United States any patented
invention during the term of the patent therefor, infringes the patent.”45 These
five activities all have one thing in common—they are carried out by the
accused infringer and they encompass every limitation (or element) described
in the specified patent claim. This Comment focuses on direct infringement,
which can be accomplished through literal infringement or nonliteral
infringement.46
Literal infringement occurs when each and every limitation of the
claimed invention is present in another’s product or process.47 “One proves
direct infringement by a mapping process of sorts, demonstrating that the
defendant’s accused product or process meets every limitation of the claim
considered individually.”48 In other words, the accused infringer’s product or

42

35 U.S.C. § 102. For a more detailed discussion of how the America Invents Act changes
our patent system from first-to-invent to first-to-file, see Robert A. Armitage, Understanding
the America Invents Act and its Implications for Patenting, 40 AIPLA Q. J. 1 (2012).
43
35 U.S.C. § 103 (2015).
44
35 U.S.C. § 154(a)(2) (2015).
45
35 U.S.C. § 271(a) (2015).
46
See LOREN & MILLER, supra note 14, at 262.
47
Cybor Corp. v. FAS Technologies, Inc., 138 F.3d 1448, 1467 (Fed. Cir. 1998).
48
See LOREN & MILLER, supra note 14, at 262.
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process must contain or use every element defined in the patent claim to be
considered direct infringement. For example, if a patent claim is for a widget
X comprising sections A, B, and C, an inventor would directly infringe on
the claim if she made widget Y comprised of sections A, B, and C.
Additionally, if the inventor made a widget Z comprised of sections A, B, C,
and D, this would also infringe upon the patent claim of widget X.49 In order
to determine if there has been literal infringement, the court will use a twostep test: “First, the claims are properly construed and then those construed
terms are compared to the accused product.”50 That is to say, the court will
first examine the claims to determine what is actually being claimed and then
compare those claims to the unauthorized product or process. If the construed
claims match the accused product, then there is literal infringement.
Conversely, nonliteral infringement can occur when an unauthorized
party’s product or process does not literally meet every limitation in a patent
claim.51 This ideology is known as the doctrine of equivalents. As the Federal
Circuit has noted, “[a] claim of infringement under the doctrine of equivalents
modifies [the infringement analysis] . . . by requiring that the fact finder
determine whether differences between particular elements of the accused
device and the asserted claims are insubstantial.”52 For example, if a patent
claimed the use of a laser pointer to be used for cat exercise, would an
unauthorized party be infringing on that patent if they used a laser pointer to
exercise their dog? The patent does not literally claim a dog, but a dog may
be considered the equivalent of a cat. In order to determine whether an alleged
equivalent is an insubstantial change, courts use the function/way/result
test.53 This test looks at “whether the alleged equivalent performs
substantially the same function, in substantially the same way, to achieve
substantially the same result.”54 Using this test, courts can determine whether
or not a product or process may nonliterally infringe upon a patent. Through
these protections, patent holders are protected from the unauthorized use of

49

Cybor, 138 F.3d at 1467.
University of Pittsburgh of Commonwealth System of Higher Educ. v. Varian Medical
Sys., 561 Fed. Appx. 934, 942 (Fed. Cir. 2014).
51
Cybor, 138 F.3d at 1467
52
Id.
53
See LOREN & MILLER, supra note 14, at 272.
54
Id.
50
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their invention, as well as the unauthorized use of an equivalent to the
patented invention.55
II. PATENT LAW AND CANNABIS
As discussed above, an invention or process must be new, useful, and
nonobvious in order to be patentable.56 Additionally, the invention or process
must be a patentable subject matter.57 But what if the subject matter is illegal
or prohibited? What if the subject matter is seen as “immoral” by some
people? While the Constitution and federal law do not specify a legality or
“moral” requirement for patents, the courts have had some thoughts on the
matter.58
A.

Cannabis Patents

In his opinion in Lowell v. Lewis in 1817, Justice Story created the
doctrine of “moral utility.”59 In Lowell, Justice Story heard a dispute
regarding patent infringement on a water pump design, which seemed pretty
standard on its face.60 However, Justice Story decided to use this clash to add
a new condition to the patent utility requirement—an inventor must establish
his invention as “new and useful,” not merely superior to current or
previously existing iterations of a product.61 Additionally, Justice Story
expanded that idea in an infamous passage:
All that the law requires is, that the invention should not be
frivolous or injurious to the well-being, good policy, or sound
morals of society. The word ‘useful,’ therefore, is
incorporated into the act in contradistinction to mischievous
or immoral. For instance, a new invention to poison people, or
to promote debauchery, or to facilitate private assassination,
is not a patentable invention.62

55

Cybor, 138 F.3d at 1467.
35 U.S.C. § 101 (2015).
57
Id.
58
See generally Lowell v. Lewis, 15 F. Cas. 1018 (Story, Circuit Justice, C.C.D. Mass. 1817)
(creating the requirement of moral utility for patents); Juicy Whip, Inc. v. Orange Bang, Inc.,
185 F.3d 1364 (Fed. Cir. 1999) (dismissing Justice Story’s “moral utility” requirement).
59
Lowell, 15 F. Cas. at 1019.
60
Id.
61
Id.
62
Id.
56
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This moral utility requirement influenced patent cases for the next century
and half, protecting society from the moral evils of gambling gadgets 63 and
rakes,64 until the Federal Circuit dismissed Justice Story’s antiquated views
in the 1999 case Juicy Whip, Inc. v. Orange Bang, Inc.65
The patent at issue in Juicy Whip was a “post-mix” beverage
dispenser that kept beverage syrup concentrate and water in separate
containers until the drink was ready to be dispensed.66 Conversely, a “premix” beverage dispenser stores syrup concentrate and water (that have
already been mixed together) in a display reservoir bowl until it’s ready to be
dispersed.67 The main point of contention in Juicy Whip was a fake display
bowl used with the “post-mix” dispenser that created the illusion of the “premix” dispenser and led customers to believe that the “fluid contained in the
bowl is the actual beverage that they are receiving.”68 While the “post-mix”
beverage dispenser may deceive some customers, the Federal Circuit held
that the patent was valid and that patents would no longer be denied based on
the grounds of morality.69 The court reasoned that it was the place of the states
to decide “by which the health, good order, peace and general welfare of the
community are promoted,” and that patent laws were not intended to displace
those state powers.70 Thus, the moral utility requirement in patent law was
undone. While there may be some debate throughout the country on whether
or not marijuana is “moral,” the outcome of that debate has no standing
(anymore) on whether or not marijuana is patentable.
Further confirming the fact that the moral utility requirement is dead
is the existence of the ‘507 patent, which is held by the U.S. Department of

63

See, e.g., Nat’l Automatic Device Corp. v. Lloyd, 40 F. 89 (C.C.N.D. Ill. 1889) (automatic
toy racehorse used in gambling establishments); Reliance Novelty Co. v. Dworzek, 80 F.
902 (C.C.N.D. Cal. 1897) (card-playing slot machine); Schultze v. Holtz, 82 F. 448
(C.C.N.D. Cal. 1897) (coin return device for slot machine); Meyer v. Buckley Mfg. Co., 15
F. Supp. 640 (N.D. Ill. 1936) (lottery ticket dispenser).
64
See Fowler v. Swift, 3 Ind. 188 (1851) (finding the patent invalid because consumer was
told rake was more efficient than other rakes).
65
Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364 (Fed. Cir. 1999).
66
Id. at 1365.
67
Id.
68
Id. at 1366.
69
Id. at 1367 (“[Y]ears ago courts invalidated patents ... on the ground that they were
immoral ... but that is no longer the law.”).
70
Id. at 1368–69 (quoting Webber v. Virginia, 103 U.S. 344, 347–48 (1880)).
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Health, and Human Services.71 That patent is currently being utilized by
KannaLife Sciences, a late-stage biotechnology development firm, to
develop new therapeutic agents with neuroprotectant and neuromodulation
benefits through the use of medicinal cannabinoids.72 The company is
currently working on research and development of a drug to treat Hepatic
Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE), both
of which are oxidative stress related diseases that affect the cognitive and
behavioral functions of the brain, as well as the brain’s overall wellness.73
While it is certainly ironic that the federal government denies any “accepted
medical utility” for marijuana74 while simultaneously holding a patent for that
same utility, the existence of the ‘507 patent highlights the value of marijuana
patents and the need for medical research. The U.S. Patent and Trademark
Office has issued over 500 cannabis-related patents since 2000, relating to
strains of marijuana-related plants, chemical formulations, medical
treatments, and devices used to make and/or consume marijuana products.75
However, the true validity of these patents may be unknown.76 Due to the
limited information available regarding prior inventions and questions as to
what information is known in the cannabis industry, the patent office may be
granting patents that are actually invalid.77 Additionally, the patent office
may be allowing overly broad cannabis patents, which could result in patents
that cover many strains and could stifle competition.78 Thanks to an
upcoming case in the District of Colorado, we may get some answers to these
validity questions.
B.

United Cannabis Corp. v. Pure Hemp Collective, Inc.

On July 30th, 2018, United Cannabis Corporation (UCANN) filed a
Complaint for Patent Infringement against Pure Hemp Collective, Inc. (Pure
71

U.S. Patent No. 6,630,507 (filed Feb. 2, 2001) (patenting cannabinoids as antioxidants and
neuroprotectants as treatment for Alzheimer's, Parkinson's, HIV, dementia, and other
progressive brain diseases).
72
See generally The Company, KANNALIFE, https://www.kannalife.com/company (last
visited Mar. 29, 2019).
73
Id.
74
21 U.S.C. § 812(b)(1), (c)(10) (2015).
75
See Malathi Nayak, Cannabis Industry Seeks Clarity in Intellectual Property Haze
(Corrected), BLOOMBERG BNA (July 27, 2018), https://www.bna.com/cannabis-industryseeks-n73014481143/.
76
Id.
77
Id.
78
Id.
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Hemp) in the U.S. District Court for the District of Colorado.79 Pure Hemp is
a Colorado-based company that makes and sells plant-based remedies that
combine hemp extract with natural blends of ingredients.80 UCANN is a
biotechnology company in Golden, Colorado that is “dedicated to the
development of phyto-therapeutic based products.”81 UCANN is suing Pure
Hemp for infringing on its ‘911 Patent, which claims “various liquid
formulations of highly enriched extracts of plant cannabinoids.”82 The ‘911
Patent was issued to UCANN’s Chief Technologies Officer, Tony Verzura,
and UCANN’s Chief Executive Officer, Earnie Blackmon, on August 15,
2017.83 This patent is entitled “Cannabis extracts and methods of preparing
and using same,” and it claims various liquid cannabinoid formulations,
including those “wherein at least 95% of the total cannabinoids is cannabidiol
(CBD).”84 UCANN claims in its suit that it purchased one of Pure Hemp’s
5000mg products (Pure Hemp’s Vina Bell) and ran chemical composition
tests on it to determine the cannabinoid formulations.85 According to
UCANN, these tests revealed that Pure Hemp’s product contained a
cannabinoid formulation wherein at least 95% of the total cannabinoids were
CBD, which directly infringed upon one or more claims of the ‘911 Patent,
specifically claim 10: “A liquid cannabinoid formulation, wherein at least
95% of the total cannabinoids is cannabidiol (CBD).”86 Following this
discovery, UCANN sent Pure Hemp a letter to inform Pure Hemp of their
infringement on the ‘911 Patent and to offer a licensing agreement.87
UCANN claims that Pure Hemp has continued to actively advertise, promote,
and sell its infringing product, despite knowledge of the infringement.88
Pure Hemp has also filed an Answer to UCANN’s complaint
(amended on November 5, 2018) in which Pure Hemp denies any
79

Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis Corp. v.
Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017).
80
Our Legacy, PURE HEMP COLLECTIVE, https://purehempcollective.com/our-story/ (last
visited Mar. 29, 2019).
81
UCANN: UNITED CANNABIS, https://www.unitedcannabis.us/ (last visited Mar. 29,
2019).
82
Complaint for Patent Infringement and Demand for Jury Trial at 1, United Cannabis (No.
1:18-cv-01922-NYW).
83
Id. at 3.
84
Id. at 4.
85
Id. at 5.
86
Id. at 6.
87
Id.
88
Id.
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infringement on the ‘911 Patent.89 Specifically on the Willful Infringement
claim, Pure Hemp “denies that it infringes or has infringed any valid,
enforceable patent claim.”90 Pure Hemp’s answer claims that UCANN’s ‘911
Patent is not valid because naturally occurring compounds (such as CBD) do
not qualify as patentable subject matter due to the Supreme Court’s decision
in Molecular Pathology v. Myriad Genetics.91 Not only does claim 10 of
UCANN’s ‘911 Patent apply to isolated products of nature, but UCANN’s
complaint also admits that cannabinoids “occur naturally in the cannabis
plant.”92 Moreover, Pure Hemp claims that UCANN’s ‘911 Patent should not
be valid because the ideas covered in it are not new.93 Citing studies and
experiments from the 1940s,94 a U.S. Patent granted in 1942,95 and numerous
pharmaceutical companies that have been selling CBD formulations that are
at least 98% pure CBD since at least October 2011,96 Pure Hemp claims that
the nearly pure CBD liquid compositions that are claimed in the ‘911 Patent
are not new due to the fact that they were on sale and in use for years before
the earliest priority date of the ‘911 Patent.97
In addition to the ‘911 Patent being invalid due to non-patentable
subject matter and novelty, Pure Hemp claims that UCANN is attempting to
monopolize the market for liquid CBD products, due to the extensive scope
of the claims in the ‘911 Patent.98 Pure Hemp claims that:
Claim 10 is so broad, in fact, that UCANN could likely
attempt to assert it against (1) any farmer growing high-CBD
chemovar cannabis who knows the cannabis will be used to
make liquid formulations, (2) any midstream processor of
high-CBD chemovar cannabis, (3) any producer of liquid
Defendant’s First Amended Answer, Defenses, and Counterclaims, United Cannabis Corp.
v. Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017).
90
Id. at 4.
91
Id. at 9; Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
(holding that claims directed to isolated, naturally occurring compounds do not qualify as
patentable subject matter).
92
Defendant’s First Amended Answer, Defenses, and Counterclaims, supra note 89, at 9.
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Id.
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the 1940s.”).
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Id. (“[T]he United States Patent Office granted U.S. Patent No. 2,304,669, titled Isolation
of Cannabidiol.”).
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Id. at 8 (claiming that Echo Pharmaceuticals B.V., Tocris Bioscience, and Sigma-Aldrich
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CBD products, (4) any seller or reseller of liquid CBD
products, (5) any purchaser of liquid CBD products, or (6) any
user of liquid CBD products.99
Thus, in addition to Pure Hemp’s affirmative defenses that the ‘911 Patent is
invalid, Pure Hemp filed a counterclaim under the Sherman Act claiming that
the ‘911 Patent would grant UCANN monopoly power over the liquid CBD
product market.100
Not only has Pure Hemp filed its answer and counterclaim against
UCANN, it also filed a motion for partial summary judgment on November
29, 2018.101 Pure Hemp is requesting early partial summary judgment that
claims 10, 12, 14, 20-22, 25, 27, 28, and 33 of the ‘911 Patent are invalid
because they are “directed to patent-ineligible natural phenomena.”102 In Pure
Hemp’s statement of facts, it claims that: (1) cannabis plants naturally contain
differing quantities of cannabinoids; (2) cannabidiol (CBD),
tetrahydrocannabinol (THC), and cannabinol (CBN) are cannabinoids that
are found naturally in cannabis plants; (3) CBD and THC are the
cannabinoids that are usually produced in the greatest abundance; (4)
standard principles of pharmaceutical formulation can be used to prepare
liquid dosage forms; (5) methods of computing cannabinoid content are well
known to those skilled in the art; and (6) the Fourth Decennial Revision of
the Pharmacopoeia of the United States of America, which was published in
1864, provides directions for “preparing a liquid Tinctura Cannabis (or
Tincture of Hemp) based on a Purified Extract of Hemp.”103
Using the framework set forth by the Supreme Court in Alice v. CLS
Bank, Pure Hemp argues that the ‘911 Patent claims (specifically the claims
that were mentioned earlier) are invalid because they fail to “contain an
inventive concept sufficient to transform the claimed naturally occurring
phenomena into a patent-eligible application.”104 The test from Alice is a twostep test: (1) courts must “determine whether the claims at issue are directed
99
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101
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102
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to one of those patent-ineligible concepts;”105 and (2) if the answer to step
one is “yes,” then the courts must ask: “[w]hat else is there in the claims
before us?”106 Pure Hemp claims (and the ‘911 Patent agrees) that CBD,
THC, and CBN are cannabinoids that are found naturally in the cannabis
plant.107 Additionally, Pure Hemp claims that neither the liquid formulation
limitation nor the “percent of total cannabinoid” limitation found in the ‘911
Patent provide an inventive concept that would make the ‘911 Patent claims
valid.108 Both of these limitations are routine and well-known to those skilled
in the art, which is admitted in the ‘911 Patent. Thus Pure Hemp argues that
claims 10, 12, 14, 20-22, 25, 27, 28, and 33 should not be valid since these
claims are “directed to patent-ineligible natural phenomena without anything
more that would constitute an eligible inventive concept.”109
C.

Outlook After UCANN v. Pure Hemp

How this suit will play out is unknown at this time. What is known
though, is that any outcome may have far-reaching consequences, due to the
potential to set a precedent for how federal courts will handle marijuanarelated patents in the future.110 This case between UCANN and Pure Hemp
is the first case involving a patent for a cannabis-based extract to reach the
federal court system.111 Looking to Pure Hemp’s Answer and Motion for
Partial Summary Judgment, it appears the court should invalidate the ‘911
Patent, or at least the claims at issue in Pure Hemp’s motion. Validating the
claims in the ‘911 Patent would likely give UCANN a monopoly over the
liquid CBD market, as well as impede innovation in the CBD arena.112 While

See Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014). The test in Alice is
used for “distinguishing patents that claim laws of nature, natural phenomena, and abstract
ideas from those that claim patent-eligible applications of those concepts.” Id.
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Id. at 9–12 (highlighting Pure Hemp’s additional argument that claim 31 should be invalid
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judges have addressed that “[i]t goes without saying that patents have adverse
effects on competition”113 and “the essence of a patent grant is the right to
exclude others from profiting by the patented invention,”114 patents are also
supposed to drive innovation.115
Patent law attempts to strike a balance between seemingly competing
areas by rewarding innovation without disproportionately impeding
competition.116 As discussed earlier, a patent grants certain rights to the
patent-holder, which allows her to exclude others from “making, using,
offering for sale, or selling the invention” while the patent is valid.117 “But
just as exclusion has always been the means, the diffusion of innovation has
always been the desired end.”118 Unfortunately, when an invalid patent has
been granted, the patent grants the same exclusionary rights to impede
competition, but doesn’t grant the same reward to innovation. “This presents
a problem because while our patent system attempts to strike a balance
between encouraging innovation and suppressing competition, that balance
is thrown off when an invalid patent issues. The invalid patent suppresses
competition without enhancing innovation.”119 As Judge Learned Hand so
aptly put, an invalid patent can be compared to a scarecrow—deterring
competition and innovation even without doing anything.120 Not only can an
invalid patent deter competition in the market, it can also impact attempts to
improve on products. Competitors who are fearful of infringement litigation
may decide not to invest in research and development in an area that is
covered by an invalid patent or patents.121 This uncertainty in the scope of
one’s intellectual property rights can lead to a chilling effect by leaving
innovators unclear whether or not they are infringing upon a “pioneer’s
intellectual property right.”122 Stifling technological advancement, regardless
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of the field, harms consumers and harms society. Competitors who fear an
infringement suit may attempt to innovate around a patent in order to create
a non-infringing product or invention. Some judges view this process as a
benefit of the patent system, but it’s often not an effective use of a limited
research budget.123 “Other disputes arise because the set of potentially
relevant patents is large, the scope of the claims is vague, and many of the
claims might be invalid. Under these conditions, designing around patents is
difficult and clearing the rights can be prohibitively expensive.”124 In short,
when an invalid patent, or a patent with invalid claims, such as the ‘911
Patent, is granted or upheld, innovation suffers.125 However, even if the ‘911
Patent is invalidated, as long as cannabis is still illegal under federal law,
innovation will naturally be hindered.
III. FUTURE OF CANNABIS AND CANNABIS-RELATED PATENTS
A.

Legality of Cannabis

Cannabis, more commonly known as marijuana, has had a
distinguished history in America. Early settlers to America used the cannabis
stalk to produce hemp: a multifaceted material that can be used to make
numerous products such as clothing, paper, and rope.126 While the stalk of
the cannabis plant was historically used as a material in manufacturing, the
flower has had many medicinal, recreational, and spiritual uses through the
years.127 In fact, the medicinal use of cannabis was recognized as providing
enough medical benefits that cannabis was added to the United States
Pharmacopeia in 1850 due to its remedial value.128 However, starting in the
early 1900s, fear began to grow that the use of cannabis, as well as alcohol

State Indus., Inc. v. A.O. Smith Corp., 751 F.2d 1226, 1236 (Fed. Cir. 1985) (“One of the
benefits of a patent system is its so-called ‘negative incentive’ to ‘design around’ a
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1339, 1355 (Fed. Cir. 1999) (observing that “patent law encourages competitors to design or
invent around existing patents”).
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and opium, would lead to addiction, violence, and overdoses.129 By the time
Congress passed the Marihuana Tax Act in 1937,130 every state in America
had already enacted laws that criminalized the possession and sale of
marijuana.131 The Marihuana Tax Act didn’t outlaw the possession or sale of
marijuana, but it did require all buyers and sellers of marijuana to register
with federal authorities and pay an annual tax.132 The extra work imposed by
the Act, along with the aggressive fines and punishments,133 effectively led
to a prohibition on cannabis, as shown by the removal of cannabis from the
United States Pharmacopeia and other medical reference texts by 1942.134
After the Marihuana Tax Act was declared unconstitutional in
135
1969, the Controlled Substances Act (“CSA”) was passed by Congress in
1970 as a pseudo replacement.136 The CSA placed all controlled substances
into five categories, or Schedules, based on the medicinal value, harmfulness,
and potential for abuse.137 Because cannabis was effectively no longer being
used for medicinal purposes, it was placed in Schedule I, which made it illegal
for doctors to medically prescribe it.138 This means that cannabis is in the
same category as heroin, ecstasy, and LSD because of a high potential for
abuse, an absence of accepted medical utility, and a lack of accepted safety
standards for cannabis use under medical supervision.139 Remarkably, opium,
cocaine, and methamphetamine are categorized into a less restrictive
Schedule than cannabis.140 There have been numerous petitions to the Drug
Enforcement Agency (DEA) to reschedule marijuana.141 A 2002 petition
requested that marijuana be removed from Schedule I because “cannabis has
an accepted medical use in the United States, is safe for use under medical
supervision, and has an abuse potential and a dependency liability that is
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lower than Schedule I or II drugs.”142 As per CSA rescheduling provisions,
the DEA requested a scientific and medical evaluation of marijuana from the
Department of Health and Human Services (DHHS) after it received the
petition.143 After completing the evaluation, the DHHS came to the
determination that “marijuana has a high potential for abuse, has no accepted
medical use in the United States, and lacks an acceptable level of safety for
use even under medical supervision” and recommended that it remain in
Schedule I.144 Thus, the DEA denied the petition and kept marijuana as a
Schedule I drug, where it remains today.145
While cultivation, distribution, and possession of marijuana remains
illegal under federal law, that hasn’t stopped a growing number of states from
enacting marijuana-related laws of their own. In 2012, Colorado and
Washington became the first two states to legalize recreational marijuana
use.146 Since then, eight other states (as well as Washington, D.C.) have
legalized the use of recreational marijuana for adults over the age of 21:
Alaska, California, Maine, Massachusetts, Nevada, Oregon, Michigan, and
Vermont.147 Additionally, 33 states have legalized marijuana for medical
use.148 Even though these states are allowing marijuana use in their respective
states, that doesn’t mean that it’s legal under federal law.
B.

Federalism and the Supremacy Clause

There have been a few instances showcasing the ability of the federal
government to regulate marijuana use in a state where marijuana has been
legalized—notably in the 2005 Supreme Court case Gonzales v. Raich.149 In
this case, the respondents included Monson, who was cultivating and
consuming her own marijuana, and two California residents, who were using
medical marijuana to treat serious medical conditions, as authorized under
California’s medical marijuana statute.150 Despite concluding that Monson’s
142
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use of marijuana was legal under California law, DEA agents and county
deputy sheriffs raided Monson’s house and destroyed her marijuana plants
under the authority of the CSA.151 Respondents sued the U.S. Attorney
General and the head of the DEA, arguing that enforcement of the CSA
prevented “them from possessing, obtaining, or manufacturing cannabis for
their personal medical use” and violated “the Commerce Clause, the Due
Process Clause of the Fifth Amendment, the Ninth and Tenth Amendments
of the Constitution, and the doctrine of medical necessity.”152 The Supreme
Court ultimately upheld the federal government’s authority to prohibit the use
of marijuana, despite compliance with California law, since the CSA
classifies cannabis as “contraband for any purpose.”153 The Court concluded
that Congress has a “rational basis” for believing that the intrastate possession
and manufacture of cannabis would “substantially affect interstate
commerce,” and therefore was authorized in regulating its use under the
Commerce Clause.154 The Court’s decision in Gonzales affirmed the federal
government’s authority to regulate marijuana, but it did not restrict the ability
of state governments to create their own marijuana laws, nor did the Court
address whether Congress intended the CSA to preempt state medical
marijuana statutes.155
While the U.S. Supreme Court has recognized Congress’s
constitutional authority to pass the existing federal restrictions on marijuana,
principles of federalism prevent the federal government from requiring that
states actively support, or participate in, applying the federal law. 156 The
Tenth Amendment has been interpreted as protecting state sovereignty when
the federal government’s Article I powers are limited.157 The Tenth
Amendment prohibits the federal government from “commandeering” state
government for federal purposes,158 or from “commandeering” state officers
for purposes of carrying out federal law.159 Given these restrictions, Congress
may not statutorily direct states to enact prohibitions on marijuana or repeal
151
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existing exemptions for recreational or medical marijuana. Even though the
federal government is prohibited from requiring states to adopt laws
supportive of federal policy, preemption generally prevents states from
creating laws that contradict federal law.160 The Supremacy Clause of the
Constitution decrees that where state and federal laws are incompatible,
federal law will preempt state law.161 There are three traditional categories of
preemption (express preemption, conflict preemption, and field
preemption),162 but there is a presupposition against preemption when it
comes to the exercise of “historic police powers of the States.”163 While it
would appear that a state law that permits an activity that is expressly
prohibited by federal law would necessarily create an incompatibility
between state and federal laws, the preemptive power of the CSA is limited
by statute to situations where “there is a positive conflict between [the CSA]
and that State law so that the two cannot consistently stand together.”164 As
stated by Todd Garvey in a report prepared for members of Congress:
Instead, the relationship between the federal ban on marijuana
and state medical marijuana exemptions must be considered
in the context of two distinct sovereigns, each enacting
separate and independent criminal regimes with separate and
independent enforcement mechanisms, in which certain
conduct may be prohibited under one sovereign and not the
other. Although state and federal marijuana laws may be
“logically inconsistent,” a decision not to criminalize—or
even to expressly decriminalize—conduct for purposes of the
law within one sphere does nothing to alter the legality of that
same conduct in the other sphere.165
This preemption issue has yet to be addressed in federal court, but state courts
have reached differing results on whether state programs issuing ID cards for
medical marijuana users are preempted by federal law. In County of San
160
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Diego v. San Diego NORML, a California appellate court found that the ID
provisions of California’s medical marijuana law did not conflict with the
CSA because the ID cards did not “insulate the bearer from federal laws.”166
Conversely, in Emerald Steel Fabricators v. Bureau of Labor and Industries,
the Oregon Supreme Court held that a state law issuing medical marijuana ID
cards was preempted by the CSA.167 The Court reasoned that the law
amounted to the state “[a]ffirmatively authorizing a use [for marijuana] that
federal law prohibits,” and therefore the state law created an “obstacle” to the
purposes of the CSA.168
There are significant preemption questions between the CSA and state
marijuana laws that need to be answered. Under the Obama Administration,
these preemption questions were not answered. While Obama was in office,
the Department of Justice took a relaxed approach to enforcing federal
marijuana laws as long as certain criteria were met.169 Through a 2013 memo
written by former Deputy Attorney General James Cole, federal prosecutors
were instructed to limit their investigations and resources to only watch for
certain violations, such as distribution to minors or distribution across state
lines.170 However, in January of 2018, former Attorney General Jeff Sessions
issued a new memo that rescinded the Cole memo and instructed “all U.S.
Attorneys to enforce the laws enacted by Congress and to follow wellestablished principles when pursuing prosecutions related to marijuana
activities.”171 While this move allows federal prosecutors to go after statelegal marijuana at their own discretion, it still remains to be seen whether or
not Session’s memo will lead to more marijuana prosecutions. While the use
of Department of Justice memos as a defense to estop marijuana-related
prosecution has not prevented prosecution,172 federal judges have used the
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2013 Cole Memo as justification for lenient sentencing guidelines.173 As
evidenced by current DOJ memos, the current Trump Administration has not
adopted the same stance towards marijuana as the Obama Administration, but
at this time, state marijuana laws remain in place and have not been
preempted under the Supremacy Clause.
C.

Cooperative Federalism

Change is likely coming to the marijuana laws in the United States,
but what will these changes be? As stated earlier, more than half of the states
have enacted state-level legislation aimed at legalizing some use for
marijuana—either medical or recreational.174 While state legislators have
kept up with the public support for marijuana, the federal government has
been slow to react.175 Numerous federal marijuana-related bills have been
introduced in Congress recently but none have gained much traction.
Separately, these bills proposed to: (1) reschedule marijuana as a Schedule II
drug and allow states to operate medical marijuana programs without federal
interference;176 (2) end federal criminal penalties and civil asset forfeiture for
individuals and businesses complying with state marijuana laws;177 (3)
eliminate all federal marijuana crimes, except for shipping or transporting
marijuana into a state where it is illegal;178 (4) legalize marijuana at the
federal level and give oversight authority to the Bureau of Alcohol, Tobacco,
Firearms and Explosives;179 and (5) federally legalize marijuana and impose
a 25% excise tax on recreational marijuana sales.180 While there have been
several opportunities for Congress to enact these laws or some version of
them, Congress does not appear inclined to end or curtail the federal
See United States v. Dayi, 980 F. Supp. 2d 682, 689 (D. Md. 2013) (“The Court therefore
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prohibition of marijuana. Since a complete end of marijuana prohibition or a
rescheduling under the CSA seem unlikely (especially under the current
administration), a federal approach that cooperates with state law could be a
realistic alternative.
Cooperative federalism has been described as “a partnership between
the States and the Federal Government, animated by a shared objective.”181
In other words, cooperative federalism permits state and federal laws to work
together towards a group solution, instead of conflicting with each other.182
Using this approach, Congress could amend the CSA to allow states to opt of
out its regulations, provided that they enact state law that meets certain
criteria or requirements. If states choose not to enact their own marijuanarelated laws, the state would still be governed by CSA regulations. This
approach can already been found in several federal statutes, including the
Clean Water Act183 and the Clean Air Act.184 Under the Clean Water Act,
states are granted primary responsibility for water quality standards, but the
federal government is permitted to take a more active role if the state fails to
adhere to Environmental Protection Agency (EPA) mandates.185 Similarly,
under the Clean Air Act, each state has the primary responsibility for the air
quality and pollution within its geographic area.186 States are permitted to
enact and carry out their own air pollution prevention plans, as long as those
plans meet the requirements of the Clean Air Act.187 If the state plans do not
meet the requirements of the Clean Air Act, then the federal plan will be put
into place instead.188 Both the Clean Air Act and the Clean Water Act express
congressional intent to have state and federal governments work together to
prevent pollution, but neither Act requires state action.189 States may choose
to do nothing and be subject to federal regulation, or they may choose to enact
their own regulations.
Amending the CSA to allow state and federal governments to enforce
and regulate marijuana together, rather than contradicting one another, would
181
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allow the federal government to influence marijuana regulations while
allowing states to independently enact their own state laws.190 “Federal law
would supplement state law only when states defer to federal law or fail to
satisfy federal requirements. Just as the EPA works with states to enforce air
and water pollution laws, federal agencies could continue to cooperate with
opt-out states and local governments to enforce marijuana laws.”191 This
approach would give the federal government influence over regulatory
priorities of the states that decide to craft their own legislation.192 Notably,
this approach (or similar approaches) have been proposed by several
prominent scholars as a “politically viable middle ground.”193 However, most
of those scholars propose state-opt-out-plans that would allow states to
completely legalize marijuana use (as long as certain federal priorities are
met).194 This Comment proposes that a cooperative federalism approach
should be used to promulgate the usage of marijuana in the medical and
research fields. Under this approach, states would be able to opt out of the
CSA if they enacted laws that regulated marijuana in the medical field or for
research purposes. Similarly, this modification to the CSA would effectively
legalize medical marijuana and legalize the use of marijuana for research
purposes in all states that do not (or choose not to) enact their own state laws
regarding marijuana. Utilizing this approach would be a safe middle ground
between full decriminalization and full federal regulation, and would allow
research and medical testing to continue (or begin) without worries of federal
or state prosecution. Allowing unfettered access for researching and medical
testing would take away much of the uncertainty and unknowns in the
marijuana field.
Additionally, there would certainly be value in a standard regulatory
framework that communicates the strain, THC, or CBD levels, as well as
other important characteristics, given the number of different marijuana
strains in existence.195
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The primary obstacle in administering marijuana in medicine,
however, is the uncertainty that currently undergirds medical
marijuana strains at legal dispensaries. Certain strains are
higher in the chemicals that are beneficial for chronic pain or
other therapeutic qualities which don't get users high. Many
patients who seek treatment with marijuana when traditional
pharmaceuticals don't adequately address their medical needs
don't want to be stoned, and they face difficulties in obtaining
consistent inventory.196
Freeing medical professionals and researchers from the threat of federal
prosecution will allow for less uncertainty in the marijuana market and lead
to more advances in medicine and genetic studies.197 As we stand right now,
with the illegality of marijuana creating a void of scientific research,
researchers and organizations have come to wide-ranging conclusions
regarding the effects of marijuana. Some researchers claim that marijuana has
been shown to have a wide range of useful medical properties, so it should
not be classified as a Schedule I substance.198 On the other side of the map,
some researchers have claimed that marijuana is dangerously addictive.199
Furthermore, based on a study funded by the National Institute of Drug Abuse
(NIDA), one group has claimed that “chronic marijuana use causes the frontal
cortex of the brain to shrink.”200 Regardless of the differing opinions on
marijuana use, gaps in cannabis research will continue to exist until standards
and clinical trials are accepted and used.
196
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While there may be fears of the potential aftermath of any federal
marijuana legalization, we can look at our neighbors to the North as a possible
signpost of what to expect.201 While recreational use of marijuana in Canada
is now permitted, marijuana used to be federally prohibited through the
Controlled Drugs and Substances Act.202 However, in 2001, Canada enacted
the Marihuana Medical Access Regulations (MMAR) which authorized
possession of dried marijuana “for the medical purpose of the holder.”203
MMAR allowed Canadian residents over the age of 18 to possess medical
marijuana if they had authorization from the Minister, and it allowed
residents to manufacture marijuana if they had the proper license to
produce.204 Following the MMAR, the Canadian Parliament passed a new set
of medical marijuana regulations in 2013: the Marihuana for Medical
Purposes Regulations (MMPR).205 These new regulations resulted in the
termination of the prior MMAR and shifted medical marijuana production
away from personal growers towards corporate production of medical
marijuana.206 Because of these new regulations, the Canadian medical
marijuana industry experienced a shift towards a commercial model, which
is similar to the heavily regulated prescription drug retailers.207 While Canada
has now legalized recreational marijuana,208 America can look to the previous
enactments of MMAR and MMPR as policies to learn from.
D.

Patent Innovation

While legalizing marijuana at the state level is a step in the right
direction, innovation that is available through patent protections does not
amount to much when federal enforcement actions are still possible. Despite
the fact that the USPTO has issued patents for marijuana-related inventions
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and processes—as evidenced by the ‘911 Patent—there are still concerns
among inventors and patent attorneys due to the federal illegality of
marijuana.209
First, some of the inventions can be used only for illegal
purposes under federal law. Specifically, inventions
particularly designed to be used in association with marijuana,
and that can only be used for such purpose, would only be
useful for illegal purposes. Nonetheless, some of the
inventions can be used outside the marijuana industry.
Second, the subject matter of some marijuana-related
inventions is illegal; meaning the invention itself is illegal.
Finally, in some cases, the application claims illegal subject
matter and practicing the invention is illegal.210
Specifically in regards to the application itself, there are risks involved in
merely filing the application. As part of an application an inventor must
describe the invention or process in detail and provide enough information to
enable the invention, which could provide a federal prosecutor with a
significant amount of evidence of a CSA violation.211 This risk also extends
to patent attorneys. Aiding a marijuana business in its business affairs, such
as applying for a patent, could be deemed a violation of the CSA and a case
of professional misconduct.212 Thus, it seems expected that there would be a
natural hesitation in pursuing and defending marijuana-related patents.
Additionally, even if business does secure a marijuana patent, that patent may
end up giving an imagined benefit to the patent holder. While the outcome of
UCANN v. PureHemp may help to exemplify what benefits are afforded to
marijuana patent holders, the fact remains that the risk will continue to exist
as long as marijuana is illegal under federal law. “Even though it theoretically
creates an enforceable right, the continuing federal prohibition operates as a
substantial impediment to the enforcement of that right and to the possibility
of a remedy.”213
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While there is some debate between practitioners and academics on
the effectiveness of certain patents in aiding innovation, patents are typically
seen as beneficial in technological growth.214 This has been reaffirmed by
some through assertions that “[more] patents materially spur [more]
innovation”215 and that “technological innovation and economic growth” are
undercut when patent filings diminish.216 Broadly, this can be summed up by
the policy stance that “more patents equals more innovation.”217
Additionally, the chilling of these patent filings—especially in the growing
marijuana industry—can undermine the invention of potentially groundbreaking innovations, which commonly arise from newer companies.218
Although it is clear that the rate of individual patenting has
been decreasing in the United States over time, it is widely
believed that individuals and small entities have an important
impact on the innovation ecosystem--perhaps an outsized
impact. This is for several reasons. First, there is some
evidence that the inventions from smaller entities are more
likely to be disruptive in nature, moving the pace of
technological change forward. Second, in some industries,
such as high technology and pharmaceuticals, small
companies and individuals serve as important innovation
inputs into larger, established companies.219
Due to the risk of federal prosecution, and the unknowingness as to the full
benefits afforded to a marijuana-related patent, these small entities and
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individuals are likely hesitant to publicly share their research and marijuana
use through the patent system. Thus it appears that this chilling effect on
marijuana-related patents is depriving the public important research.
Important research that can create market competition and potentially
ground-breaking innovations. The public will continue to be deprived of this
research and innovation unless something changes in the current federal
scheme.
CONCLUSION
By their very nature, patents are exclusionary. A patent grants the
right to exclude others from making use of an invention or process. But
patents are also tools to promote innovation. However, when an invalid patent
is granted, the patent becomes an exclusionary tool that also chills innovation.
UCANN’s ‘911 Patent is an invalid patent that is chilling innovation in the
cannabis market—specifically in the liquid CBD market. By invalidating the
‘911 Patent, the federal courts can help to promote innovation once again.
But the ‘911 Patent is not the only thing hindering innovation in the cannabis
market. While the Controlled Substances Act continues to prohibit cannabis
at a federal level, researchers and medical professionals will be unsure of the
legality of their actions. This naturally leads to another chilling effect in the
use of cannabis in the medical field and within research firms. By amending
the Controlled Substances Act to allow cannabis for medical and research
purposes, and allowing states to opt out of the Act, the federal government
can help to promote innovation in the cannabis market. This approach could
eliminate the gaps in cannabis research and knowledge that continue to
plague the U.S. to this day.

